Delays in the management of lung cancer P J M George
Surgery remains the treatment of choice for patients with definitive treatments such as surgery while also ensuring higher and more uniform standards of management genearly stage lung cancers. 1 The aim is to remove all malignant tissue before local invasion and/or distant metastatic spread erally. has occurred. Current practices are therefore directed towards diagnosing and staging lung cancers as early and efficiently as possible, while also ensuring that patients Prospects of earlier treatment through earlier with operable tumours undergo surgery promptly. The diagnosis Standing Medical Advisory Committee has recently reAn alternative approach to achieving earlier treatment commended that the interval between a patient's first is by diagnosing lung cancers at earlier stages in their presentation to his general practitioner and resection development. Billing and Wells advocated the esshould be no longer than 6-8 weeks.
2 tablishment of screening programmes.
3 Trials of lung canBilling and Wells recently presented data on the time cer screening, however, have produced rather disappointing taken from first presentation to surgery in a consecutive results in the past. The most celebrated trials were conseries of 38 patients with suspected or proven primary lung ducted in the 1970s at the Mayo Clinic, 9 Johns Hopkins 10 cancers. 3 The mean interval was found to be 109 days, of and Memorial-Sloane Kettering Hospitals. 11 Each trial inwhich an average of 58 days was taken up with diagnostic volved over 10 000 men, aged 45 years or more, who were and staging investigations. The authors expressed concern regarded as being at risk of developing lung cancer on the that delays of this magnitude, which are twice that regarded basis of their smoking histories. The trials were designed as acceptable, 2 only serve to heighten the disruption to to assess the value of screening using sputum cytological patients' lives and possibly jeopardise their chances of cure.
testing in combination with regular chest radiography. In There can be little doubt that patients with suspected the trials conducted at the Johns Hopkins and Memorial lung cancer suffer in many ways while undergoing diagSloane-Kettering Hospitals subjects were randomised to nostic and staging investigations. This is sufficient juseither annual chest radiography alone (control group) or tification alone for expediting their management. Although annual chest radiography with four monthly sputum cytothere is no evidence to suggest that management delays logical tests (screened group). At the Mayo Clinic the adversely affect clinical outcomes, it seems likely that delays control group underwent annual chest radiography and of four months, which approximate to one tumour volume sputum cytological tests while the screened group underdoubling time for non-small cell carcinoma, 4 will ensure went these investigations every four months. The results that some patients will require more extensive resections were broadly similar; although more cases of early stage while others with borderline operable tumours at prelung cancer were detected in the screened populations with sentation will become inoperable. Common sense therefore improved five year survivals, the eventual mortality from dictates that we should manage our patients more effilung cancer was identical to that of the control groups. [12] [13] [14] ciently. The improved survival was therefore attributed to lead time and length time bias. The prevailing view at the time of these trials was that chest radiography was unlikely to be an effective screening The need for change There is now a growing body of evidence to suggest that tool and so its usefulness was not evaluated. Chest radiographic screening has subsequently been evaluated in casethe management of lung cancer in the UK falls short of accepted standards of practice in several other important control studies 15 16 and has not been shown to have a significant impact on lung cancer mortality. Similarly, chest respects.
5 Reviews of unselected groups of patients with lung cancer have recently shown wide variations in manradiographic screening for lung cancer in chromate workers has failed to demonstrate a benefit of screening when the agement practices which relate to the specialty interest of the hospital clinician to whom the patient has been referred 6 survival figures of patients compliant and non-compliant with screening who later developed lung cancer were comand facilities that are available locally in the patient's hospital of origin. 7 pared. 17 Despite the disappointment of these trials, interest con-A substantial number of patients are not referred to chest physicians or consultants with an interest in thoracic tinues in developing techniques that might allow lung cancers to be diagnosed at earlier stages when prompt oncology and there is evidence to suggest that these patients are less likely to receive active treatments such as surgery, intervention may improve the chances of cure. At Johns Hopkins Hospital sputum samples obtained during the radiotherapy, or chemotherapy.
5 6 As the proportion of patients with lung cancer who undergo resection in the screening programme were banked in an archive while follow up data were collected on the providers of these UK is substantially less than in Europe and North America, 2 there must be concern that some patients with specimens. This has allowed investigators to evaluate more recently developed tumour markers using material where operable tumours are being denied the chance of curative surgery in our present system. the eventual clinical outcome is known. 18 For example, immunostaining with murine monoclonal antibodies to Billing and Wells 3 argued the case for establishing specialist centres as proposed by the Department of Health. 8 small cell and non-small cell antigens has shown a strong correlation between positive staining and the eventual deThey suggest that patients should be managed intensively as inpatients in these centres with the aim of completing velopment of lung cancer. 19 Using samples obtained, on average, 20 months before the detection of cancer and their diagnostic and staging investigations within 1-2 days. Such a system would have the advantage of expediting from comparable controls who did not develop cancer, group.bmj.com on April 3, 2017 -Published by http://thorax.bmj.com/ Downloaded from immunostaining was found to be 91% sensitive and 88% may also improve the outcome of this common and lethal disease. specific.
Similarly, a polymerase chain reaction based assay has conducted in Europe to evaluate the possible advantages
